EUVIMEDEUVIMED entdecken
Crossref

Predictors of outcome in patients receiving stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancers

Akanksha Anup, Manisha Bhandare, Vikram Chaudhari, Rahul Krishnatry, Shailesh Shrikhande, Vikas Ostwal, Anant Ramaswamy, Akshay Baheti, Mukta Ramadwar, Reena Engineer

International Journal of Hepatobiliary and Pancreatic Diseases · 2016

DOI: 10.5348/100098z04aa2022ra ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Hepatobiliary and Pancreatic Diseases, 2016. Verfasst von Akanksha Anup und 9 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate the outcomes in borderline resectable (BRPC) and locally advanced pancreatic cancer (LAPC) receiving neoadjuvant chemotherapy (NACT) and stereotactic body radiotherapy (SBRT) followed by surgery when feasible.

Methods

Consecutive patients of BRPC and LAPC treated from May 2015 to December 2019 were included. All underwent NACT with FOLFIRINOX/Gem Nabpacli 4–6 cycles, followed by SBRT with differential planning target volume (PTV) dose of 36–46 Gy over 5–6 fractions. Local progression-free survival (LPFS), distant metastasis free survival (DMFS), overall survival (OS) were estimated.

Results

Eighty-nine (50 BRPC and 39 LAPC) patients with a median follow-up of 26.0 months were identified. Of the 33 (37%) patients surgically explored and 19 (47.5%) BRPC and 4 (10.2%) LAPC patients underwent surgery, 21 (91.6%) had R0 resection. The median OS and disease free survival (DFS) of patients who underwent surgery was 28.4 ± 3.4 and 23 ± 5 months, respectively. The patients who did not undergo surgery the median OS and LPFS was 19 ± 1.4 and 12 ± 1 months, respectively. Patients who underwent surgery in BRPC cohort had significantly better DFS (23 vs 12 months, p=0.001) and OS (28 vs 19 months, p=0.035). On multivariate analysis, Eastern Cooperative Oncology Group (ECOG) < 2 [hazard ratio (HR): 2.77 (1.2–6.2; 0.014)], head location [3.7 (1.44–9.6; 0.007)], and radiological response post-NACT-SBRT [4.38 (1.08–17.7; 0.039)] were significant predictors of outcome in both the cohorts. No grade ≥3 late radiotherapy (RT)-related toxicities were seen.

Conclusion

Stereotactic body radiotherapy is safe and effective for local control and aids in improving the outcomes in pancreatic cancers.

Zitieren

APA

Anup, A., Bhandare, M., Chaudhari, V., Krishnatry, R., Shrikhande, S., Ostwal, V., Ramaswamy, A., Baheti, A., Ramadwar, M., & Engineer, R. (2016). Predictors of outcome in patients receiving stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancers. International Journal of Hepatobiliary and Pancreatic Diseases. https://doi.org/10.5348/100098z04aa2022ra

Vancouver

Anup A, Bhandare M, Chaudhari V, Krishnatry R, Shrikhande S, Ostwal V, et al. Predictors of outcome in patients receiving stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancers. International Journal of Hepatobiliary and Pancreatic Diseases. 2016. doi:10.5348/100098z04aa2022ra

BibTeX
@article{Anup2016,
  author = {Anup, Akanksha and Bhandare, Manisha and Chaudhari, Vikram and Krishnatry, Rahul and Shrikhande, Shailesh and Ostwal, Vikas and Ramaswamy, Anant and Baheti, Akshay and Ramadwar, Mukta and Engineer, Reena},
  title = {Predictors of outcome in patients receiving stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancers},
  journal = {International Journal of Hepatobiliary and Pancreatic Diseases},
  year = {2016},
  doi = {10.5348/100098z04aa2022ra}
}
Kostenlos starten →